amifostine + cisplatin + vinorelbine

This is a combination chemotherapy regimen consisting of three agents: - **Amifostine** is a cytoprotective adjuvant, primarily used to reduce the cumulative renal toxicity associated with repeated administration of platinum-based chemotherapies like cisplatin. It acts as a prodrug that is dephosphorylated in tissues to an active free thiol metabolite, which scavenges free radicals and protects normal (non-tumor) cells from the toxic effects of chemotherapy and radiation[9][10][5]. - **Cisplatin** is a platinum-based antineoplastic agent that forms DNA crosslinks, leading to apoptosis in rapidly dividing tumor cells. - **Vinorelbine** is an anti-mitotic small molecule that inhibits microtubule assembly by binding tubulin, thereby arresting cell division at metaphase and inducing apoptosis in malignant cells[6]. This combination has been studied for use in advanced non-small cell lung cancer (NSCLC), particularly stage IIIB-IV disease. Amifostine's role within this regimen is primarily as a nephroprotectant against cisplatin-induced renal toxicity while vinorelbine and cisplatin act synergistically as cytotoxic agents targeting tumor proliferation[1][5]. The regimen has demonstrated activity and feasibility in clinical trials for NSCLC.